The US FDA has declined to approve Merck and Daiichi Sankyo's 'guided missile' cancer drug, patritumab deruxtecan, intended for treating non-small cell lung cancer (NSCLC). The rejection, announced on June 27, 2024, was due to issues at a third-party manufacturer. This decision marks a significant setback for the first project under the Merck-Daiichi partnership.
US FDA declines to approve Rocket Pharma's immune disorder gene therapy https://t.co/iXlVCYICuC https://t.co/ua0t5lSLHO
Daiichi's lung cancer ADC rejected by FDA in blow to first project under Merck partnership https://t.co/S9XHq4zEXi
FDA rejects @Merck and @DaiichiSankyoUS’ #HER3 ADC patritumab deruxtecan for #NSCLC because of problems at a third-party manufacturer. #oncology https://t.co/xydfExZfVC https://t.co/jVB5tjUmCP
#US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug https://t.co/bRFjHJgHAg https://t.co/BbXbCdE9qi